Gritstone Oncology is a personalized cancer immunotherapy company that is leveraging insights about the nature of anti-tumor immune responses to develop personalized neoantigen immunotherapies, which harness the patient’s own immune system to narrowly focus an attack on unique non-self markers displayed by the tumor to attack it. With our unique approach to immuno-oncology, focused on the two key dimensions instrumental to the successful development of neoantigen-targeted therapy, we are developing next-generation personalized immunotherapies to fight cancer in patients with the most difficult-to-treat tumors.